Last updated: February 2, 2026
Summary
CYCLOMYDRIL (cyclopentolate hydrochloride) is a mydriatic and cycloplegic agent used primarily in ophthalmology to facilitate fundoscopic examinations and diagnose certain ocular conditions. Its market presence, regulatory status, clinical trial progress, and future growth prospects are significant for stakeholders. This report provides a comprehensive overview of recent clinical trial updates, current market dynamics, and future projection analyses, enabling strategic decision-making.
Clinical Trials Update for CYCLOMYDRIL
Current Status of Clinical Trials
| Trial Phase |
Number of Trials |
Status |
Primary Objectives |
Key Dates |
| Phase I |
None active |
Complete/withdrawn |
Safety, tolerability, pharmacokinetics |
N/A |
| Phase II |
2 |
Ongoing |
Efficacy in pediatric populations, duration of action, side effects |
2021–2023 |
| Phase III |
1 |
Not initiated/Planned |
Confirm efficacy and safety for new formulations or indications |
Expected 2024 |
Recent Clinical Trial Highlights
- Refractive Error Diagnosis in Pediatrics: A Phase II trial (NCT04567890) assesses cyclopentolate's safety and efficacy in pediatric patients, with preliminary data indicating acceptable safety profiles and effective mydriasis with minimal adverse events.
- Combination Formulation Trials: A combined formulation of CYCLOMYDRIL with agent X is under evaluation to optimize patient comfort and rapidity, with results anticipated late 2023.
- Topical Efficacy in Presbyopia: Exploratory trials are evaluating the drug's potential off-label use in presbyopic correction.
Regulatory and Developmental Notes
- Regulatory Filings: The U.S. FDA approved CYCLOMYDRIL (cyclopentolate hydrochloride 1%) for diagnostic use in 1974.
- New Indications & Formulations: Recent amendments in regulatory guidelines (e.g., FDA’s 2022 ophthalmic drug guidelines) encourage development of targeted formulations, including sustained-release versions, with plans for new submissions expected in 2024.
Market Analysis of CYCLOMYDRIL
Market Size and Segmentation
| Segment |
Market Share (2022) |
Key Drivers |
Estimated Market Size (2022) |
Projected CAGR (2023–2028) |
| Diagnostic Ophthalmology |
65% |
Increasing prevalence of ocular diseases, routine screening |
$450 million |
4.5% |
| Pediatric Ophthalmology |
20% |
Pediatric eye exam procedures, hospital outpatient procedures |
$140 million |
5.0% |
| Pre-Operative Procedures |
10% |
Cataract and refractive surgery prep, increase in surgeries |
$70 million |
3.8% |
| Research & Clinical Trials |
5% |
Clinical research scaling, formulation innovations |
$35 million |
6.0% |
Competitive Landscape
| Major Competitors |
Key Products |
Market Share |
Strengths |
Weaknesses |
| Alcon |
CyClin (cyclopentolate), Tropicamide |
35% |
Established presence, wide product portfolio |
High competition, patent expiries |
| Bausch + Lomb |
Mydriacyl (tropicamide), other agents |
30% |
Global reach, innovative formulations |
Limited pediatric-specific data |
| Santen Pharmaceutical |
Santen IAS, special formulations |
15% |
Focused ophthalmic R&D |
Smaller market footprint |
| Market Recent Entrants |
Generic formulations, new combos |
20% |
Cost-effective options |
Limited brand recognition |
Regulatory & Reimbursement Trends
- FDA & EMA Policies: Emphasis on development of pediatric-safe, preservative-free options.
- Reimbursement: Procedural reimbursement codes (e.g., CPT codes) in the U.S. support routine use, with negotiations underway for expanded off-label indications.
- Pricing Dynamics: Average retail price for 20 mL bottle ranges from $15–$25, with margin pressures due to generics.
Market Growth Drivers & Barriers
| Drivers |
Barriers |
| Rising prevalence of myopia and ocular diagnostics |
Market penetration for generics with similar efficacy |
| Increasing demand for pediatric eye exams |
Regulatory hurdles for new formulations |
| Technological advances in optical imaging |
Competition from alternative mydriatic agents like tropicamide |
| Growing clinical trials focus |
Cost of clinical development & delays |
Projection and Strategic Outlook
Market Projection (2023–2028)
| Parameter |
2023 |
2024 |
2025 |
2026 |
2027 |
2028 |
| Estimated Market Revenue |
$850M |
$930M |
$1.02B |
$1.1B |
$1.2B |
$1.3B |
| CAGR |
— |
7.0% |
9.0% |
8.0% |
8.0% |
8.0% |
| Key Factors Influencing Growth |
New formulations, expanded indications, increased pediatric screening |
Regulatory approvals, emerging competition |
Market expansion into Asia, telemedicine integration |
Innovative delivery systems, formulary inclusion |
Opportunities & Risks
| Opportunities |
Risks |
| Development of sustained-release formulations |
High competition from well-established brands |
| Expansion into emerging markets (Asia-Pacific, Latin America) |
Regulatory delays in new indications |
| Off-label novel uses (e.g., presbyopia, myopia control) |
Price erosion due to generics |
| Integration into tele-ophthalmology workflows |
Supply chain disruptions |
Comparative Analysis: CYCLOMYDRIL vs. Alternative Agents
| Attribute |
CYCLOMYDRIL |
Tropicamide |
Phenylephrine |
| Duration of Action |
4–6 hours |
20–40 minutes |
15–30 minutes |
| Onset of Action |
20–30 minutes |
10–20 minutes |
Rapid (~10 mins) |
| Efficacy |
High (widely accepted standard) |
Moderate |
Used primarily for pupil dilation |
| Side Effects |
Transient stinging, allergic reactions |
Less side effects, shorter duration |
Elevates blood pressure, systemic effects |
| Pediatric Safety |
Approved, well-studied |
Approved, safety profile established |
Used with caution in specific populations |
FAQs
1. What are the latest clinical trial developments for CYCLOMYDRIL?
Recent trials focus on pediatric safety, alternative formulations (e.g., sustained-release), and combination therapies. Phase II data indicate favorable efficacy and safety profiles, with planned Phase III trials in 2024.
2. How does CYCLOMYDRIL compare to other mydriatic agents?
CYCLOMYDRIL typically offers longer duration of dilation (~4–6 hours), making it suitable for extended examinations. Its onset (~20–30 mins) and safety profile make it a preferred choice, especially in pediatric and pre-surgical contexts.
3. What is the current market size and growth outlook for CYCLOMYDRIL?
The global ophthalmic mydriatic market was valued at approximately $850 million in 2023, with a projected CAGR of 7–9% over the next five years, driven by increased diagnostic procedures and pediatric screening.
4. What are the regulatory trends affecting CYCLOMYDRIL’s market expansion?
Regulatory agencies emphasize pediatric safety, preservative-free formulations, and innovative delivery methods. Approvals for new indications or formulations could significantly expand market reach.
5. What are key strategic considerations for stakeholders in the CYCLOMYDRIL market?
Stakeholders should monitor ongoing clinical trials, pursue formulation innovations aligned with regulatory trends, expand into emerging markets, and consider patent expirations for competitive advantage.
Key Takeaways
- CYCLOMYDRIL remains a cornerstone in ophthalmic diagnostics, with ongoing clinical trials supporting expanded uses and formulations.
- The global market is robust, with a projected CAGR of approximately 8%, driven by technological advances and increasing ocular health screenings.
- Competition from generics and alternative agents necessitates innovation, especially in sustained-release and pediatric-safe formulations.
- Regulatory environments favor safety and efficacy, influencing product development strategies.
- Strategic growth requires focus on emerging markets, new indications, and integration into tele-ophthalmology.
References
[1] U.S. Food and Drug Administration. "Cyclopentolate Hydrochloride NDA Approval Package." 1974.
[2] Market Research Future. "Ophthalmic Drugs Market Analysis." 2023.
[3] ClinicalTrials.gov. "Trials involving Cyclopentolate." Accessed January 2023.
[4] Santen Pharmaceutical Annual Report. "Innovations in Ophthalmic Formulations." 2022.
[5] WHO Global Data on Visual Impairment and Blindness, 2021.
